ISRCTN29319366已完成2 期
Thymostimulin in advanced hepatocellular carcinoma: a phase II trial
Martin-Luther-University Halle-Wittenberg (Germany)0 个研究点目标入组 44 人开始时间: 2007年12月21日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 44
研究概览
简要总结
2008 results in https://pubmed.ncbi.nlm.nih.gov/18366627/ (added 30/12/2020)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Biopsy- or image-proven locally advanced or metastatic hepatocellular carcinoma not amenable to or failing established treatment
- •2. Two-dimensional measurable lesion on imaging
- •3. Life expectancy greater than 3 months
- •4. Age 18 to 80 years
排除标准
- •1. Pregnancy/lactation
- •2. Active second malignancy
- •3. Severe concomitant disease (e.g. New York Heart Association [NYHA] grade III - IV, serum creatinine level greater than 300 µmol/l)
- •4. Severe decompensated liver function (bilirubin greater than 5 mg/dl, International normalised ratio [INR] greater than or equal to 2.3)
- •5. Unable to give informed consent
研究者
相似试验
已完成
2 期
TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular CarcinomaHepatocellular CarcinomaNCT06232759Guangxi Medical University56
Unknown
3 期
Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular CarcinomaHepatocellular CarcinomaNCT00921531Fudan University200
Unknown
3 期
Adjuvant Therapies for Patients With HCC and MVIHepatocellular CarcinomaNCT02436902Guangxi Medical University240
Unknown
4 期
Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative ResectionCurable Hepatitis B Virus-Related Hepatocellular CarcinomaNCT02281266Jia Fan360
撤回
1 期
Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T CellsAdvanced Hepatocellular CarcinomaNCT05628545Guangdong GD Kongming Biotech LLC